Bing Zhang, Peng Chen, Mengping Shen, Qunxing Ding and Haiyan Zhu
Neonatal purulent meningitis is a significant cause of neonatal disability and death. The early diagnosis and
effective treatment are critical for neonatal purulent meningitis. Procalcitonin (PCT) is currently used as a clinical
diagnosis marker of inflammation and infection, such as sepsis. Due to the lower immunity of neonates and the
atypical symptoms of neonatal purulent meningitis, it is challenging to obtain reliable information of the development,
diagnosis, treatment and prognosis of neonatal purulent meningitis. This study monitored the dynamic change of the
PCT levels in 48 neonatal patients after the standard treatment and found out that the PCT level may not be a
distinguish diagnosis marker but a useful indicator for efficacy of the treatment and prognosis specifically in neonatal
purulent meningitis.
